Tag:
PharmaEngine
Latest Headlines
Latest Headlines
Merrimack ropes back international rights to cancer drug in $220M pact
When Merrimack Pharmaceuticals bought out Hermes Biosciences near the end of 2009, it touted the prospects for the UCSF spinout's lead drug, MM-398, then in mid-stage studies for multiple cancer
